Clinical Trial to Evaluate the Efficacy of Umbilical Cord Blood to Improve Outcomes for Children with Autism Spectrum Disorder

This program of research is sponsored by the Marcus Foundation.

Researchers at the Duke University Medical Center are conducting a program of research to evaluate the efficacy of autologous and allogeneic cord blood for improving outcomes of individuals with autism spectrum disorder.  The first study examined the safety and efficacy of using autologous cord blood to treat young children with autism spectrum disorder and assessed the feasibility of various outcome measures to determine which measures can be used as primary and secondary endpoints for a randomized phase 2 clinical trial (DukeACT) that is currently underway. Cord blood cells can be collected from the placenta and stored for future usage in cord blood banks for cellular therapies or blood stem cell transplantation. Previous research has shown that cord blood cells can help reduce inflammation and signal cells to help repair damaged brain areas. The goal of this study was to investigate whether similar success will be shown in children with ASD. The results of this study have been published in Stem Cells Translational Medicine. You can view the publication here.

Please contact 844-800-CORD or cordbloodtherapyinfo@dm.duke.edu  or autismresearch@duke.edu for more information. 

 

Pro00052449

Criteria
Children ages 2-6 with a clinical diagnosis of ASD. Banked autologous cord blood also required.
Enrollment status
Completed